Public-Private Partnerships in Drug Development for Underdeveloped Countries: An Interview with Craig Wheeler, President of Chiron's Biopharmaceutical Division

Cambridge Quarterly of Healthcare Ethics 12 (4):429-433 (2003)
  Copy   BIBTEX

Abstract

In an effort to create a mechanism for addressing a critical need of providing medicines for economically developing countries, the Chiron Corporation and the Global Alliance for TB Drug Development have entered into an innovative public-private partnership. In the following interview, Craig Wheeler discusses the origins and nature of this agreement that could set a pattern for how corporations and nonprofit organizations can work together in drug development

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 92,347

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Industry, innovation and social values.Harvey E. Bale - 2005 - Science and Engineering Ethics 11 (1):31-40.
Private-to-private corruption.Antonio Argandoña - 2003 - Journal of Business Ethics 47 (3):253 - 267.

Analytics

Added to PP
2010-08-24

Downloads
35 (#459,692)

6 months
6 (#530,615)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

No citations found.

Add more citations

References found in this work

No references found.

Add more references